secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-037497
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review
--------------------------------------------------------------------------------

- Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
- Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.
- Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.
- Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.
- TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/0001213900-26-037497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/ea0284372-8k_endralife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer